Industry Growth Insights published a new data on “Benign Prostatic Hyperplasia Testing Market”. The research report is titled “Benign Prostatic Hyperplasia Testing Market research by Types (Urinalysis, Prostate-Specific Antigen (PSA) Blood Test, Urodynamic Test, Cystoscopy), By Applications (Hospitals, Diagnostic Centers, Clinics, Research Institutes), By Players/Companies AEternaZentaris, Astellas Pharma, Eli Lilly and Company, IntelGenx Technologies Corp, Nymox Pharmaceutical Corporation, Protox Therapeutics, Quest PharmaTech”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Benign Prostatic Hyperplasia Testing Market Research Report
By Type
Urinalysis, Prostate-Specific Antigen (PSA) Blood Test, Urodynamic Test, Cystoscopy
By Application
Hospitals, Diagnostic Centers, Clinics, Research Institutes
By Companies
AEternaZentaris, Astellas Pharma, Eli Lilly and Company, IntelGenx Technologies Corp, Nymox Pharmaceutical Corporation, Protox Therapeutics, Quest PharmaTech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Benign Prostatic Hyperplasia Testing Market Report Segments:
The global Benign Prostatic Hyperplasia Testing market is segmented on the basis of:
Types
Urinalysis, Prostate-Specific Antigen (PSA) Blood Test, Urodynamic Test, Cystoscopy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Diagnostic Centers, Clinics, Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AEternaZentaris
- Astellas Pharma
- Eli Lilly and Company
- IntelGenx Technologies Corp
- Nymox Pharmaceutical Corporation
- Protox Therapeutics
- Quest PharmaTech
Highlights of The Benign Prostatic Hyperplasia Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Urinalysis
- Prostate-Specific Antigen (PSA) Blood Test
- Urodynamic Test
- Cystoscopy
- By Application:
- Hospitals
- Diagnostic Centers
- Clinics
- Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Benign Prostatic Hyperplasia Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Benign Prostatic Hyperplasia (BPH) is a condition in which the prostate gland becomes enlarged and may produce too much semen. BPH can cause difficulty urinating, especially at night, and can lead to other health problems. A doctor may perform a test to determine if you have BPH.
Some of the key players operating in the benign prostatic hyperplasia testing market are AEternaZentaris, Astellas Pharma, Eli Lilly and Company, IntelGenx Technologies Corp, Nymox Pharmaceutical Corporation, Protox Therapeutics, Quest PharmaTech.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Benign Prostatic Hyperplasia Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Benign Prostatic Hyperplasia Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Benign Prostatic Hyperplasia Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Benign Prostatic Hyperplasia Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Benign Prostatic Hyperplasia Testing Market Size & Forecast, 2018-2028
4.5.1 Benign Prostatic Hyperplasia Testing Market Size and Y-o-Y Growth
4.5.2 Benign Prostatic Hyperplasia Testing Market Absolute $ Opportunity
Chapter 5 Global Benign Prostatic Hyperplasia Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Benign Prostatic Hyperplasia Testing Market Size Forecast by Type
5.2.1 Urinalysis
5.2.2 Prostate-Specific Antigen (PSA) Blood Test
5.2.3 Urodynamic Test
5.2.4 Cystoscopy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Benign Prostatic Hyperplasia Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Benign Prostatic Hyperplasia Testing Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Diagnostic Centers
6.2.3 Clinics
6.2.4 Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Benign Prostatic Hyperplasia Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Benign Prostatic Hyperplasia Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Benign Prostatic Hyperplasia Testing Analysis and Forecast
9.1 Introduction
9.2 North America Benign Prostatic Hyperplasia Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Benign Prostatic Hyperplasia Testing Market Size Forecast by Type
9.6.1 Urinalysis
9.6.2 Prostate-Specific Antigen (PSA) Blood Test
9.6.3 Urodynamic Test
9.6.4 Cystoscopy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Benign Prostatic Hyperplasia Testing Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Diagnostic Centers
9.10.3 Clinics
9.10.4 Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Benign Prostatic Hyperplasia Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Benign Prostatic Hyperplasia Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Benign Prostatic Hyperplasia Testing Market Size Forecast by Type
10.6.1 Urinalysis
10.6.2 Prostate-Specific Antigen (PSA) Blood Test
10.6.3 Urodynamic Test
10.6.4 Cystoscopy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Benign Prostatic Hyperplasia Testing Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Diagnostic Centers
10.10.3 Clinics
10.10.4 Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Benign Prostatic Hyperplasia Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Benign Prostatic Hyperplasia Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Benign Prostatic Hyperplasia Testing Market Size Forecast by Type
11.6.1 Urinalysis
11.6.2 Prostate-Specific Antigen (PSA) Blood Test
11.6.3 Urodynamic Test
11.6.4 Cystoscopy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Benign Prostatic Hyperplasia Testing Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Diagnostic Centers
11.10.3 Clinics
11.10.4 Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Benign Prostatic Hyperplasia Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Benign Prostatic Hyperplasia Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Benign Prostatic Hyperplasia Testing Market Size Forecast by Type
12.6.1 Urinalysis
12.6.2 Prostate-Specific Antigen (PSA) Blood Test
12.6.3 Urodynamic Test
12.6.4 Cystoscopy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Benign Prostatic Hyperplasia Testing Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Diagnostic Centers
12.10.3 Clinics
12.10.4 Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Benign Prostatic Hyperplasia Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Benign Prostatic Hyperplasia Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Benign Prostatic Hyperplasia Testing Market Size Forecast by Type
13.6.1 Urinalysis
13.6.2 Prostate-Specific Antigen (PSA) Blood Test
13.6.3 Urodynamic Test
13.6.4 Cystoscopy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Benign Prostatic Hyperplasia Testing Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Diagnostic Centers
13.10.3 Clinics
13.10.4 Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Benign Prostatic Hyperplasia Testing Market: Competitive Dashboard
14.2 Global Benign Prostatic Hyperplasia Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AEternaZentaris
14.3.2 Astellas Pharma
14.3.3 Eli Lilly and Company
14.3.4 IntelGenx Technologies Corp
14.3.5 Nymox Pharmaceutical Corporation
14.3.6 Protox Therapeutics
14.3.7 Quest PharmaTech
